Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Surgery Physician in Tampa, FL
NPI: 1417156944Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. Amod's Phone Numberphone_androidMobile
Get M.D. Amod's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
FL State Medical License
2007 - 2026
OH State Medical License
1999 - 2006
American Board of Surgery
Surgery
University Of Michigan Medical School
medschool.umich.edu
Medical School
Until 1999
University of Cincinnati Medical Center/College of Medicine
Residency • Surgery
1999 - 2006
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 72 | 82 |
| 2 | 13121Repair of wound (2.6 to 7.5 centimeters) of scalp, arms, and/or legs | 34 | 35 |
| 3 | 38900Lymph node imaging during surgery | 32 | 33 |
| 4 | 13101Repair of wound (2.6 to 7.5 centimeters) of trunk | 31 | 31 |
| 5 | 11606Removal of cancer skin growth of body, arms, or legs, more than 4.0 cm | 29 | 29 |
beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.
Authors: Andrew Lowy, Jiang Wang
Journal: Cancer Res
The Unique Clinical Characteristics of Melanoma Diagnosed in Children
Authors: Jane Messina, Vernon Sondak, Suroosh Marzban, Jonathan Zager, Damon Reed
Journal: Ann Surg Oncol
Publication Date: 2012-08-03
Lead Sponsor: Iovance Biotherapeutics, Inc.
Intervention / Treatment: BIOLOGICAL: Lifileucel
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Bristol-Myers Squibb, Stand Up To Cancer, Iovance Biotherapeutics, Inc., Prometheus Inc.
Intervention / Treatment: DRUG: Nivolumab, DRUG: Cyclophosphamide, DRUG: Fludarabine, OTHER: Tumor-infiltrating Lymphocyte Therapy, DRUG: Interleukin-2 (IL2), PROCEDURE: Tumor-infiltrating Lymphocytes (TIL)
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Regeneron Pharmaceuticals, Sanofi-Synthelabo
Intervention / Treatment: DRUG: Cemiplimab-Rwlc